Xencor, Inc. Profile Avatar - Palmy Investing

Xencor, Inc.

Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that tar…

Biotechnology
US, Monrovia [HQ]
US · Macroeconomic Factors/Risks · Forecasts

Macro

Xencor, Inc. mainly operates in US (Alpha-2: US, Alpha-3: USA)

United States
Analysis Results
B Overall Rating
19 Analyzed Indicators
B Annual Indicators Rating
16 Analyzed Indicators
B+ Monthly Indicators Rating
3 Analyzed Indicators
Breakdown

All indicators comes from high quality sources, such as the world bank, OECD, FRED and manuel datasets such as Premiums by Prof. Damodaran.

End of XNCR's Analysis
CIK: 1326732 CUSIP: 98401F105 ISIN: US98401F1057 LEI: - UEI: -
Secondary Listings
XNCR has no secondary listings inside our databases.